# US 2010/0144634 A1 · Compositions and Methods for Modulation of ADAMTS13 Activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0144634 A1
- Document ID: US20100144634A1
- Status: Published application
- Kind: A1
- Application number: 12/627,485
- Filed: 2009-11-30
- Published: 2010-06-10
- Earliest claimed: 2007-05-31
- Inventors: X. Long Zheng; Ping Zhang; Sriram Krishnaswarny; Wenjing Cao
- Web page: https://patentgrep.com/patent/US20100144634A1

## CPC

- C12Q 1/37: involving peptidase or proteinase
- C12Q 1/56: involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- G01N 2800/226: Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
- G01N 2800/2871: Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
- G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Compositions and methods are provided for the diagnosis and treatment of thrombotic thrombocytopenic purpura (TTP), stroke and myocardial infarction.

## Claims

### Claim 1

A method for analyzing the VWF cleaving action of ADAMTS13 and variants thereof, comprising:
a) providing VWF;
b) contacting said VWF with intact ADAMTS13 and truncated variants thereof under conditions suitable for enzymatic cleavage of VWF;
c) determining the amount of VWF cleavage in the presence of full length ADAMTS13 relative to that observed in the presence of said truncated variants, thereby identifying a minimal ADAMTS13 sequence suitable to effect cleavage of VWF, said method optionally being performed under flow.

### Claim 2 (depends on 1)

The method of claim 1, further comprising the addition of a test compound which modulates ADAMTS13 mediated cleavage of VWF.

### Claim 3 (depends on 2)

The method of claim 2, wherein said test compound inhibits cleavage of VWF.

### Claim 4 (depends on 2)

The method of claim 2, wherein said test compound augments cleavage of VWF.

### Claim 5 (depends on 4)

The method of claim 4, wherein said compound is Factor VIII.

### Claim 6

A method for diagnosing TTP in a patient comprising;
a) obtaining a biological sample comprising VWF and ADAMTS13;
b) subjecting said sample to vortex induced shear stress; and
c) comparing the level of VWF cleavage in said biological sample relative to an identically treated sample from a normal patient, a reduction in VWF cleavage relative to that observed in said normal patient sample being indicative of TTP.

### Claim 7 (depends on 6)

The method of claim 6, wherein said sample is selected from the group consisting of blood, serum, and plasma.

### Claim 8

A method for alleviating the symptoms of a disease in a patient in need thereof, comprising administration of an effective amount of ADAMTS13 and FACTOR VIII in a biologically compatible medium, wherein said disease is selected from the group consisting of TTP, stroke, and myocardial infarction.

### Claim 9 (depends on 8)

A method as claimed in claim 8, wherein said ADAMTS13 and said FACTOR VIII are produced recombinantly and purified.

### Claim 10 (depends on 9)

The method of claim 9, wherein said proteins are administered systemically.

### Claim 11 (depends on 9)

The method of claim 9, wherein said purified proteins are directly infused into a patient, thereby inhibiting or preventing formation of a thrombus.
